Psychiatrie pro praxi – 3/2019

www.psychiatriepropraxi.cz e33 PŘEHLEDOVÉ ČLÁNKY Farmakoterapie nealzheimerovských typů demencí PSYCHIATRIE PRO PRAXI 14. O'Brien JT, Thomas A. Vascular dementia. Lancet 2015; 386(10004): 1698–706. 15. Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR; SPS3 Investigators. Effects of long-term blood pressure lowering and dual antiplatelet tre- atment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol 2014; 13: 1177–1185. 16. Rusina R, Matěj R, et al. Neurodegenerativní onemocnění. Praha: Mladá fronta 2014: 351. 17. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Wein- traub D, Sampaio C; and the collaborators of the Parkinson's Disease Update on Non-Mo- tor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disea- se-an evidence-based medicine review. Mov Disord 2019; 34(2): 180–198. 18. Shivanand P. Review on Alzheimer's disease: its cause, symptoms, and treatment at worldwide. International Journal of Applied Biology and Pharmaceutical Technology 2009; 1(1): 112–120. 19. Šonka K. Porucha chování v REM spánku. Neurol. praxi, 2008; 9(5): 297–299. 20. Taylor DM, Barnes TRE, Young AH. The Maudsley prescribing guidelines in psychiatry. 13 th ed. West Sussex, United Kingdom: John Wiley & Sons 2018; 854. 21. Tsai RM, Boxer AL. Therapy and clinical trials in frontotemporal dementia: past, present, and future. J Neurochem. 2016; 138(Suppl 1): 211–221. 22. Youdim MB, Oh YJ. Promise of neurorestoration and mitochondrial biogenesis in Par- kinson’s disease with multi target drugs: an alternative to stem cell therapy. Exp Neurobiol 2013; 22: 167–72. 23. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet 2015; 386(10004): 1683–1697. 24. WHO 2017. http://www.who.int/features/factfiles/dementia/en/.